Weight-loss drug semaglutide accelerates recovery from brain inflammation in mice

The diabetes and weight-loss drug semaglutide can calm inflammation in the brain by coordinating a response across multiple types of cells. The findings suggest the medication might help protect against cognitive decline by reversing cellular changes associated with neurodegenerative diseases. The research was published in Nature Communications.

Inflammation in the brain, or neuroinflammation, is a natural defense mechanism that protects neural tissue from injury and infection. In a healthy system, this response is brief and highly controlled. When this inflammatory response becomes chronic or dysregulated, it contributes to neurodegenerative conditions such as Alzheimer’s disease.

Genetics research points to immune pathways as major drivers of cognitive decline over time. At the same time, metabolic conditions like obesity and type 2 diabetes independently increase the risk of developing dementia. To explore the bridge between metabolism and brain health, scientists are investigating a class of medications called glucagon-like peptide-1 receptor agonists.

Originally developed to treat diabetes and obesity, drugs like semaglutide mimic a natural hormone that regulates blood sugar and appetite. Clinical observations indicate that patients taking these medications might experience lower rates of dementia. However, researchers do not entirely understand how these drugs alter the cellular environment of the brain to provide a protective effect.

To understand the cellular mechanics behind this process, researchers Dylan M. Belmont-Rausch, Mette Q. Ludwig, and Marie A. Bentsen led a team to map how semaglutide alters the brain during an inflammatory event. The researchers first established a controlled model of brain inflammation. They injected male mice with lipopolysaccharide, a bacterial component that reliably triggers a strong immune response.

Before the inflammatory challenge, a subset of the animals received a daily dose of semaglutide for two weeks. By examining brain tissue under a microscope at different intervals, the team tracked the activity of microglia and astrocytes. Microglia act as the primary immune cells of the central nervous system, patrolling for damage and clearing cellular debris, while astrocytes help support neuronal health.

The microscopic analysis showed that semaglutide did not block the initial spike in microglial activity immediately following the bacterial trigger. Instead, the medication accelerated the recovery process. Eleven days after the inflammatory event, the mice treated with semaglutide showed reduced microglial activation in the hippocampus, a brain region central to learning and memory.

To uncover the genetic instructions driving this recovery, the researchers analyzed the RNA inside individual cell nuclei from the hippocampus. RNA carries the genetic blueprints that dictate how a cell behaves. By isolating thousands of individual nuclei and reading these blueprints, the team could tell exactly which cellular programs were turned on or off over time.

Following the bacterial challenge, the mice experienced a rush of neutrophils into the hippocampus. Neutrophils are white blood cells that usually circulate in the bloodstream to fight infections. Under normal conditions, they rarely enter healthy brain tissue, but the bacterial component caused them to breach this boundary.

Semaglutide treatment completely prevented these white blood cells from infiltrating the brain. Blood tests revealed that the medication also suppressed the release of inflammatory signaling proteins in the rest of the body. At the same time, the drug maintained the body’s levels of proteins that naturally reduce inflammation, promoting a state of immune tolerance.

Within the brain tissue itself, semaglutide reversed inflammatory genetic changes in several non-neuronal cells. This included the microglia, as well as endothelial cells that line blood vessels and pericytes that help maintain the structural integrity of the blood-brain barrier. The researchers mapped the transcription factor networks that act as master switches for these cellular programs.

The bacterial trigger activated networks related to immune defense and cellular shape changes, instructing the cells to mount a defense. The medication systematically deactivated these specific networks in the vascular and immune cells. By tracking an established set of maintenance genes, the researchers observed that the drug helped the microglia return to their baseline, resting state much faster than they would have naturally.

The team then investigated the dorsal vagal complex, a region in the brainstem that acts as a communication hub between the gut and the brain. They applied the same single-nucleus RNA sequencing technique to tissue from this area. Just as in the hippocampus, the bacterial component altered the behavior of non-neuronal cells, and semaglutide countered these changes.

The researchers identified a specific group of neurons in the brainstem that feature receptors for the medication. When exposed to semaglutide, these neurons activated genes responsible for producing anti-inflammatory chemical messengers. These neurons also produce signaling molecules associated with the body’s natural opioid and adrenaline systems.

Non-neuronal cells like microglia and endothelial cells do not possess their own receptors for the drug. The researchers suspect these brainstem neurons act as intermediaries. The neurons detect the medication and then relay protective signals to the rest of the brain’s immune and vascular systems to stand down the immune response.

To evaluate the relevance of these animal findings to human health, the researchers cross-referenced their genetic data with large databases of human DNA. They compared the genetic activity seen in the mice with genes known to increase the risk of Alzheimer’s disease in humans. The inflammatory response in the mice activated many of the exact same genes associated with human Alzheimer’s risk.

Semaglutide treatment successfully dialed down the activity of these disease-linked genes in the mice. The researchers also compared their results to postmortem brain tissue from human patients. The cellular signatures from the medicated mice countered the genetic patterns typically seen in advanced stages of human cognitive decline.

The current experiments utilized exclusively male mice, meaning the results might not fully translate to females due to hormonal differences in immune responses. The mice were also young and healthy prior to the study, which does not entirely capture the gradual aging processes involved in chronic human neurodegeneration.

The researchers measured genetic instructions and cellular markers but did not track the animals’ behavior or memory performance. Future studies will need to explore whether the cellular recovery promoted by the medication translates into measurable improvements in cognitive function. The precise communication pathways between the brainstem neurons and the broader immune system also require further mapping.

The study, “Semaglutide attenuates neuroinflammation in male mice,” was authored by Dylan M. Belmont-Rausch, Mette Q. Ludwig, Marie A. Bentsen, Stine N. Hansen, Anna Secher, Dorte Holst, Jaime Moreno, Vivek Das, Kristoffer L. Egerod, Anne-Mette Bjerregaard, Kristoffer Niss, Sarah Bau, Charles Pyke, Kevin Dalgaard, Myrte Merkestein, Franziska Wichern, Charlotte Thim Hansen, Joseph Polex-Wolf, Lotte Bjerre Knudsen, and Tune H. Pers.